Company Analysis
Sign in

uniQure N.V. (QURE)

Nasdaq: QURE · Pharmaceutical Preparations · Amsterdam · filing with the SEC since 2013
Full chart Alerts Compare
Grade4.1
◀ Past 5.1● Present 4.1▶ Future 3.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

38 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to uniQure N.V.’s names, not what it holds today.

Patents granted
38
37 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
6
Against none in 2024 and 3 in 2023
Applications published
74
8 of them in 2025
Names they are printed under
5
its holding company, a subsidiary
By yearGrantedApplications published
'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology9
Pharmaceuticals4
Medical technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
uniQure IP B.V. its holding company
NL, as the owner printed on each patent; a holding company under the name uniQure N.V.
34 granted
37 published
UNIQURE BIOPHARMA B.V. a subsidiary
NL, as the owner printed on each patent
4 granted
20 published
uniQure IP B.V. its holding company
named as the applicant on its applications, in NL; a holding company under the name uniQure N.V.
0 granted
13 published
uniQure biopharma B.V. a subsidiary
named as the applicant on its applications, in NL
0 granted
3 published
UNIQURE FRANCE a subsidiary
named as the applicant on its applications, in FR
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 2, 202512,486,496AAV vectors produced by insect cells comprising Rep52 and Rep78 coding sequences with differential codon biasesBiotechnologyuniQure IP B.V.
Oct 21, 202512,448,628Further improved AAV vectors produced in insect cellsBiotechnologyuniQure IP B.V.
Jun 3, 202512,319,924Liver-specific viral promoters and methods of using the sameBiotechnologyuniQure IP B.V.
Apr 29, 202512,285,451Means and methods for AAV gene therapy in humansPharmaceuticalsuniQure IP B.V.
Feb 4, 2025RE50,288Factor IX polypeptide mutant, its uses and a method for its productionUNIQURE BIOPHARMA B.V.
Feb 4, 202512,214,053Methods of improving adeno-associated viral transductionPharmaceuticalsuniQure IP B.V.
Oct 10, 202311,780,886Modified viral vectors and methods of making and using the sameBiotechnologyuniQure IP B.V.
Jun 6, 202311,667,931AAV capsid production in insect cellsBiotechnologyuniQure IP B.V.
Mar 28, 202311,613,765Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAVBiotechnologyuniQure IP B.V.
Sep 27, 202211,452,749Means and methods for AAV gene therapy in humansPharmaceuticalsuniQure IP B.V.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0382611Gene constructs for silencing alpha-synuclein and uses thereofBiotechnologyUNIQURE BIOPHARMA B.V.
Nov 6, 20252025/0340878METHOD AND MEANS TO DELIVER miRNA TO TARGET CELLSPharmaceuticalsuniQure IP B.V.
Sep 25, 20252025/0297278Insect cell-produced high potency AAV vectors with CNS-tropismBiotechnologyUNIQURE BIOPHARMA B.V.
Sep 25, 20252025/0297252Nucleic acid regulation of SNCABiotechnologyUNIQURE BIOPHARMA B.V.
Jul 17, 20252025/0230437Novel systems for nucleic acid regulationBiotechnologyUNIQURE BIOPHARMA B.V.
Jul 10, 20252025/0223590Nucleic acid regulation of ApoEBiotechnologyUNIQURE BIOPHARMA B.V.
Jun 5, 20252025/0179462FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTIONPharmaceuticalsUNIQURE BIOPHARMA B.V.
May 29, 20252025/0170275METHODS AND MEANS FOR THE PREVENTION AND/OR TREATMENT OF HEMOPHILIC ARTHROPATHY IN HEMOPHILIAPharmaceuticalsUNIQURE BIOPHARMA B.V.
Dec 19, 20242024/0417737METHODS AND COMPOSITIONS FOR TREATING EPILEPSYBiotechnologyUNIQURE FRANCE
Dec 5, 20242024/0398988RNAi induced C9ORF72 suppression for the treatment of ALS/FTDBiotechnologyuniQure IP B.V.
What it applied for, 2024 to 2025: Biotechnology 12 · Pharmaceuticals 5.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton QURE · research, not advice